There are literally hundreds of new drugs hitting the market each year. Why write about this particular drug? The drug bears discussion because it is the first one in 50 years to treat a disease called Lupus. Lupus is an autoimmune disease in which the immune system turns against part of the body it is designated to protect. It causes debilitating joint pain, organ damage and skin rashes. Up to now the key medication used to treat Lupus are steroids.

A team of researchers from Human Genome Sciences (HGSI) headed by William Haseltine started looking at genes and their special functions. The problem was that there was no gene known to cause Lupus. So they started thinking outside the box. Instead of finding the gene first and then its function, they looked for the function then found the gene called BLyS that is elevated in Lupus. The new drug is called Benlysta.

Analyst Upgrades

• Goldman upgraded CSX (CSX) to neutral from sell.
• General Cable (BGC) was upgraded to buy from hold at KeyBanc.
• Morgan Stanley upgraded Chart Industries (GTLS) and Dresser Rand (DRC) to overweight from equal weight.
• Blackrock (BLK) was upgraded to outperform from neutral at Macquarie.
• Credit Suisse upgraded Zions Bancorp (ZION) to neutral from underperform and GameStop (GME) to outperform from neutral.
• Honeywell (HON) was upgraded to outperform from sector perform at RBC Capital.
• Panera Bread (PNRA) was upgraded to buy from neutral at SunTrust.

Human Genome Sciences (HGSI - option chain) stock is trading lower today after briefing materials for an FDA advisory panel were released that questioned whether the benefits of Benlysta, a proposed lupus treatment from HGSI and GlaxoSmithKline (GSK), outweighed its risks. The panel will potentially vote next week on whether it thinks Benlysta should be approved, but its early skepticism might not be a good sign for HGSI and GSK and speculation surrounding the event has driven option prices through the sky. If you think this stock won't be rising too far in the coming months, then it could be a good time to look at a bearish hedged play on HGSI.

Analyst Upgrades

• Oppenheimer upgraded Teva (TEVA) to outperform from perform. The firm expects the company to generate strong 2H10 earnings and thinks the competition created by Novartis's (NVS) Gilenia will be limited.
• Citigroup upgraded Celanese (CE) to buy from hold, citing valuation and the company's move to add assets in China, as well as possible takeover interest.
• Needham raised Stereotaxis (STXS) to buy from hold as the firm thinks that strong clinical data recently announced by the company could result in faster adoption rates of its robotic surgery.
• BMO Capital upgraded Smurfit-Stone Container (SSCC) given strength in the containerboard market.
• Melco Crown (MPEL) was upgraded to buy from neutral at UBS.
• Goldman Sachs raised Temple-Inland (TIN) to buy from neutral.
• Barclays upgraded Lloyds Banking (LYG) to equal weight from underweight.

• CLSA upgraded Freeport McMoRan (FCX) to Buy from Sell and has a price target of $85 based on expectations for improved copper prices. The analyst believes China is mostly done with tightening measures and that downside in copper prices is limited.
• Jefferies upgraded Concur Tech (CNQR) to Buy from Hold due to improvements in corporate travel and structural growth drivers from international and SMB. The firm has a price target of $55 on the stock.
• Deutsche Bank upgraded ESCO Technologies (ESE) to Buy from Hold on expectations the company will announce a contract with SoCal Gas within two months. The firm upped its target for shares to $35 from $33.
• Wells Fargo (WFC) was raised to Outperform from Market Perform at FBR Capital.
• Human Genome (HGSI) was upgraded to Outperform from Neutral at Baird.
• Brown & Brown (BRO) was upgraded to Neutral from Underweight at JP Morgan.

• Canaccord downgraded Netflix (NFLX) to Hold from Buy following the Q2 report and has a $107 price target on the stock. The firm is growing more cautious on ARPU pricing pressure, higher churn rates and higher SAC.
• Deutsche Bank downgraded Airgas (ARG) to Hold from Buy following the company's Q1 results due to valuation. The firm has a $65 price target for shares. Note shares were also downgraded at Soleil this morning.
• Goldman downgraded Piper Jaffray (PJC) to Neutral from Buy and lowered its price target to $35 from $46. The firm said Piper's ROE remains below peers.
• AMB Property (AMB) was downgraded to Neutral from Buy at BofA/Merrill.
• Odyssey Healthcare (ODSY) was downgraded to Negative from Neutral at Susquehanna.
• Trina Solar (TSL) was downgraded to Outperform from Strong Buy at Raymond James.

• BofA/Merrill started Cognizant Technology (CTSH) with a Neutral rating.
• Stifel Nicolaus initiated Brigham Exploration (BEXP) with a Buy rating and $24 target.
• ThinkEquity assumed Dick's Sporting (DKS) with a Buy rating.
• Petrohawk Energy (HK) was initiated with a Perform rating at Oppenheimer.
• E.ON AG (EONGY) was initiated with a Buy rating at RBS.
• Atlas Energy (ATLS) was initiated with an Outperform rating at BMO Capital.

Analyst Upgrades

• Barrington upgraded Global Payments (GPN) to outperform from market perform following the company's Q3 results and raised earnings guidance.
• FBR Capital upgraded Foot Locker (FL) to outperform from market perform to reflect the company's improving comps and international expansion. The firm set a $17 price target for shares.
• Keefe Bruyette upgraded Legg Mason (LM) to outperform from market perform and raised its target for shares to $37 from $34.
• Acuity Brands (AYI) was upgraded to buy from hold at BB&T.
• Ann Taylor (ANN) was upgraded to hold from underperform at Jefferies.
• Waddell & Reed (WDR) was upgraded to buy from hold at Citigroup.

Human Genome Sciences (HGSI) slipped into the red right out of the gate Wednesday morning, as traders reacted to the company's latest round of clinical drug data. HGSI said that its experimental lung cancer drug, mapatumumab, was well-tolerated by patients in a study, but the drug fared no better than a placebo in disease response or progression-free survival.

Full results of the study will be presented "at an appropriate scientific meeting later in 2010," according to a company release.

Analyst Upgrades

• Deutsche Bank upgraded Viacom (VIA) to buy from hold due to valuation and expectations that share buybacks will resume this year. The firm raised its price target on shares to $37 from $28.
• Canadian Natural (CNQ) was upgraded to outperform from neutral at Credit Suisse. The firm upgraded shares based on valuation and the outlook for heavy crude.
• UBS upgraded Key Energy (KEG) to buy from neutral, citing increased E&P well spending, a possible shorter term rally in gas activity and improved utilization. Target raised to $12.50 from $9.50.
• Shire (SHPGY) was raised to outperform from perform at Oppenheimer.
• PNC Financial (PNC) was upgraded at Bernstein to outperform from market perform.
• Pacer International (PACR) was upgraded to buy from hold at BB&T.

Analyst Upgrades

• Goldman upgraded Potash (POT) to conviction buy from buy and said a "near-worst-case" scenario on 2010 potash pricing is reflected in potash valuations and that they continue to expect a fundamental potash demand recovery in 2010. Note that the firm also upgraded Mosaic (MOS) to buy from neutral. Potash's price target is $138.
• Morgan Stanley upgraded Alcoa (AA) to overweight from equal weight based on expectations for alumina to continue to rally in 2H10. The firm has a $22 target on the stock.
• Baird upgraded Seagate (STX) to outperform from neutral and raised its target to $25 from $22 based on expectations that IT hardware spend will continue to accelerate through 2010, HDD supply conditions will continue to be constrained at least into the March quarter, and that enterprise strength and favorable supply conditions will drive shares higher in 2010.
• Intel (INTC) was upgraded to overweight from equal weight at Barclays.
• Resource Capital (RSO) was raised to outperform from market perform at FBR Capital.
• Palm (PALM) was upgraded to hold from sell at Morgan Joseph.